Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...157158159160161162163164165166167...859860»
  • ||||||||||  fludarabine IV / Generic mfg., thiotepa / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation (clinicaltrials.gov) -  Jun 6, 2023   
    P2,  N=40, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Dec 2023
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal:  Adalimumab (Humira (Pubmed Central) -  Jun 5, 2023   
    Anti-tumor necrosis factor agents are widely used in treating ankylosing spondylitis, but they increase the risk of infection by suppressing the immune response. Therefore, physicians should be careful about recurrent infections in patients under anti-tumor necrosis factor agents.
  • ||||||||||  Journal:  Viability of selected microorganisms in parenteral preparations for novel systemic anti-cancer therapy. (Pubmed Central) -  Jun 5, 2023   
    Viability of the selected pathogenic microorganisms was retained in most of the tested biological and small molecule preparations used to treat cancer patients. Therefore, in pharmacy departments strict aseptic conditions should be regarded and the lack of antimicrobial activity should be considered when assigning shelf life to RTA parenteral preparations.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study. (Pubmed Central) -  Jun 5, 2023   
    These findings underscore potential opportunities for dermatologists and oncologists in The effectiveness of anti-CGRP monoclonal antibodies is almost the same between women in menopause and women of childbearing age, without appreciable differences between the different antibodies.
  • ||||||||||  Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci, Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Trial primary completion date:  Auto Stem Cell Transplant for Lymphoma Patients (clinicaltrials.gov) -  Jun 5, 2023   
    P2,  N=150, Recruiting, 
    Large amounts of cfDNA may indicate poorer prognoses for patients receiving late-line regorafenib chemotherapy. Trial primary completion date: Apr 2023 --> Sep 2023
  • ||||||||||  vepdegestrant (ARV-471) / Arvinas, Pfizer
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  ARV-471-mBC-101: A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE (clinicaltrials.gov) -  Jun 5, 2023   
    P1/2,  N=215, Recruiting, 
    Trial primary completion date: Apr 2023 --> Sep 2023 Trial completion date: Feb 2024 --> Sep 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  DeLLpro-300: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov) -  Jun 5, 2023   
    P1b,  N=41, Active, not recruiting, 
    Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 Recruiting --> Active, not recruiting | N=100 --> 41 | Trial completion date: Apr 2027 --> May 2025 | Trial primary completion date: Apr 2026 --> Mar 2023
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 (Pubmed Central) -  Jun 3, 2023   
    Recruiting --> Active, not recruiting | N=100 --> 41 | Trial completion date: Apr 2027 --> May 2025 | Trial primary completion date: Apr 2026 --> Mar 2023 Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65
  • ||||||||||  DT2216 / Dialectic Therap, MRTX1133 / Mirati, Lumakras (sotorasib) / Amgen
    Journal:  Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. (Pubmed Central) -  Jun 3, 2023   
    The inhibitors targeting G12D mutation (such as MRTX1133) have been recently developed, whereas those targeting other mutations are still lacking...In addition, we recently demonstrated that the combination of sotorasib with DT2216 (a BCL-X-selective degrader) synergistically inhibits G12C-mutated pancreatic cancer cell growth in vitro and in vivo...This chapter will review KRAS biochemistry, signaling pathways, different mutations, emerging KRAS-targeted therapies, and combination strategies. Finally, we discuss challenges associated with KRAS targeting and future directions, emphasizing pancreatic cancer.
  • ||||||||||  rocatinlimab (KHK4083) / Kyowa Kirin, Amgen
    Rocatinlimab improves SCORAD and DLQI in adults with moderate (Level 3 - Room 327) -  Jun 2, 2023 - Abstract #WCD2023WCD_3607;    
    P2
    CAE characterization and management after immune checkpoint inhibitors in KC patients is a rapidly growing field that needs specific and prospective studies. Consistent with significant EASI improvement, rocatinlimab demonstrated significant SCORAD and DLQI improvements, which were maintained for 20 weeks off-treatment, suggesting rocatinlimab may have potential for disease-modification in adults with msAD
  • ||||||||||  omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Journal:  Binding pocket dynamics along the recovery stroke of human ?-cardiac myosin. (Pubmed Central) -  Jun 2, 2023   
    The breakthrough discovery of omecamtiv mecarbil (OM) has led to an increased interest in small molecules that can target myosin and modulate its function for therapeutic purposes (myosin modulators)...Possible intermediate conformations were also identified, in remarkable agreement with experimental findings. The differences in the binding site properties observed along the transition can be exploited for the future development of conformation-selective myosin modulators.